Canada’s $3.4 billion food disruption

Dr Sylvain Charlebois: We learned this week that Apotex Inc., Canada’s largest drug manufacturer, has received approval from Health Canada to market a generic version of Ozempic. This is a pivotal moment. What began as a treatment for diabetes has quickly evolved into something far more consequential: a structural force reshaping consumer behaviour and, by extension, Canada’s agri-food economy. Are these drugs will now get cheaper…